Pimecrolimus

• Pimecrolimus is a calcineurin inhibitor that has an anti-inflammatory effect¹
• Pimecrolimus inhibits T cell activation and cytokine synthesis (IL-2, IL-4, IL-10, IFN-γ) by blocking FKBP-12 and calcineurin¹
• Pimecrolimus 0.3% ophthalmic ointment (MR-139) is currently being studied in a Phase 3 clinical trial for the treatment of adult and pediatric patients with blepharitis²

FKBP-12, FK506-binding protein 12; IFN, interferon; IL, interleukin.
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf 2. https://clinicaltrials.gov/study/NCT06400511.